Crescent Biopharma (CBIO) Treasury Shares (2014 - 2026)

Crescent Biopharma (CBIO) posted quarterly Treasury Shares of $561170.0 for Q2 2026, down 24.31% quarter-over-quarter from $741454.0 in Q4 2025.

Crescent Biopharma (CBIO) Treasury Shares (2014 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has reported Treasury Shares for 13 consecutive years, with $561170.0 the latest figure, recorded in Q2 2026.

In Q2 2026, Treasury Shares changed N/A year-over-year to $561170.0; the TTM figure through Jun 2026 stood at $561170.0 (changed N/A YoY), while the FY2025 annual figure was $741454.0, down 96.29% from the prior year.
Treasury Shares eased to $561170.0 in Q2 2026 per CBIO's latest filing, from $741454.0 in the prior quarter.
Across five years, Treasury Shares topped out at $20.0 million in Q3 2024 and bottomed at $48995.0 in Q2 2024.
Historically, Treasury Shares has averaged $4.0 million across 5 years, with a median of $210690.5 in 2022.
On a YoY basis, Treasury Shares climbed as much as 34043.68% in 2025 and fell as far as 97.81% in 2025.
Crescent Biopharma's Treasury Shares stood at $204785.0 in 2022, then plunged by 42.79% to $117157.0 in 2023, then surged by 16971.11% to $20.0 million in 2024, then plunged by 96.29% to $741454.0 in 2025, then decreased by 24.31% to $561170.0 in 2026.
Business Quant data shows CBIO's Treasury Shares at $561170.0 in Q2 2026, $741454.0 in Q4 2025, and $438386.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Crescent Biopharma	1.10 Bn	933.02 Mn	-	-

Download Data